ğŸ”¬ Doctor Mode: Gathering evidence...
ğŸ” Gathering evidence for: What is the evidence comparing SGLT2 inhibitors versus GLP-1 agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease?
ğŸ“‹ PICO Tags: diseases=[DIABETES, GLP1, VTE], decisions=[radiation, combination_therapy, physical_therapy]
ğŸ·ï¸  Query classification: general (confidence: 0%)
ğŸ“Š Abbreviation Analysis:
   Coverage: 0%
   Known: none
   âš ï¸  Unknown: GLP
   Strategy: expanded-first
   Reasoning: Unknown abbreviations detected (GLP). Prioritizing expanded terms, with abbreviated fallback.
âš ï¸  Unknown abbreviations detected: GLP
   Coverage: 0% (0/1)
   Recommendation: LLM should interpret these abbreviations in context
ğŸ”„ Generated 3 search variants for comprehensive evidence retrieval
   Original: "What is the evidence comparing SGLT2 inhibitors versus GLP-1 agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease?"
   Variant 1: "What is the evidence comparing SGLT2 (sodium-glucose cotransporter-2) inhibitors versus GLP-1 (glucagon-like peptide-1) agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease?"
   Variant 2: "What is the evidence comparing sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease?"
ğŸ¯ Primary search: "What is the evidence comparing sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease?"
ğŸ¯ Secondary search: "What is the evidence comparing SGLT2 inhibitors versus GLP-1 agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease?"
ğŸ”¬ Medical Observation Extraction: Starting...
â„¹ï¸  No specific medical observations found in query
ğŸ” Query Clarification: Starting structured extraction...
âŒ Query Clarification failed: [GoogleGenerativeAI Error]: Error fetching from https://generativelanguage.googleapis.com/v1beta/models/gemini-2.0-flash-exp:generateContent: [429 Too Many Requests] You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. To monitor your current usage, head to: https://ai.dev/rate-limit. 
* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 0, model: gemini-2.0-flash-exp
* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 0, model: gemini-2.0-flash-exp
* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_input_token_count, limit: 0, model: gemini-2.0-flash-exp
Please retry in 28.278710388s. [{"@type":"type.googleapis.com/google.rpc.Help","links":[{"description":"Learn more about Gemini API quotas","url":"https://ai.google.dev/gemini-api/docs/rate-limits"}]},{"@type":"type.googleapis.com/google.rpc.QuotaFailure","violations":[{"quotaMetric":"generativelanguage.googleapis.com/generate_content_free_tier_requests","quotaId":"GenerateRequestsPerDayPerProjectPerModel-FreeTier","quotaDimensions":{"location":"global","model":"gemini-2.0-flash-exp"}},{"quotaMetric":"generativelanguage.googleapis.com/generate_content_free_tier_requests","quotaId":"GenerateRequestsPerMinutePerProjectPerModel-FreeTier","quotaDimensions":{"location":"global","model":"gemini-2.0-flash-exp"}},{"quotaMetric":"generativelanguage.googleapis.com/generate_content_free_tier_input_token_count","quotaId":"GenerateContentInputTokensPerModelPerMinute-FreeTier","quotaDimensions":{"location":"global","model":"gemini-2.0-flash-exp"}}]},{"@type":"type.googleapis.com/google.rpc.RetryInfo","retryDelay":"28s"}]
âš ï¸  Falling back to pattern-based extraction
ğŸ” Query Clarification:
   Decision type: prognosis
   Guideline bodies: ERS
   Key drugs: none
   Key biomarkers: none
   Confidence: 50%
   âš ï¸  Warnings: Pattern-based fallback used (no LLM available)
ğŸ” Query optimization complete:
   PubMed: "(What is the evidence comparing sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease?) OR ("Diabetes Mellitus, Type 2"[MeSH Terms] OR "Cardiovascular Diseases"[MeSH Terms] OR "Glucose"[MeSH Terms])"
   Guidelines: "What is the evidence comparing sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease? guideline recommendation"
   Trials: "What is the evidence comparing sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease? randomized controlled trial"
ğŸ¯ Detected 2 clinical scenario(s) with anchor guidelines
âš“ Adding 4 Anchor Guidelines to evidence package
ğŸ“‹ International guidelines found: { WHO: 3, CDC: 3, NICE: 3, BMJ: 3, 'ACC/AHA/ESC': 5 }
ğŸ† Landmark trials found: 5
ğŸ” DailyMed: Comprehensive search for "What is the evidence comparing sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease?"
ğŸ“­ No drug names detected in query
Query not pediatric-related, skipping AAP search
ğŸ“– Searching StatPearls: "evidence comparing sodium glucose"
ğŸ”¬ Fetching clinical trials from ClinicalTrials.gov API v2...
ğŸ” PubMed search: "(What is the evidence comparing sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease?) OR ("Diabetes Mellitus, Type 2"[MeSH Terms] OR "Cardiovascular Diseases"[MeSH Terms] OR "Glucose"[MeSH Terms])" with filters:  AND 2016:2026[dp] AND humans[mh] AND hasabstract
ğŸ” PubMed search: "(What is the evidence comparing sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease?) OR ("Diabetes Mellitus, Type 2"[MeSH Terms] OR "Cardiovascular Diseases"[MeSH Terms] OR "Glucose"[MeSH Terms]) AND (systematic[sb] OR meta-analysis[pt])"
ğŸƒ Lifestyle/prevention query detected - adding guideline search
ğŸ” PubMed search: "(What is the evidence comparing sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease?) OR ("Diabetes Mellitus, Type 2"[MeSH Terms] OR "Cardiovascular Diseases"[MeSH Terms] OR "Glucose"[MeSH Terms]) AND (
    guideline[pt] OR 
    practice guideline[pt] OR 
    "clinical practice guideline"[tiab] OR
    consensus[tiab] OR 
    recommendation[tiab] OR 
    "position statement"[tiab] OR
    "consensus statement"[tiab] OR
    "clinical guideline"[tiab]
  )" with filters:  AND 2016:2026[dp] AND humans[mh]
ğŸ” PubMed search: "(What is the evidence comparing sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease?) OR ("Diabetes Mellitus, Type 2"[MeSH Terms] OR "Cardiovascular Diseases"[MeSH Terms] OR "Glucose"[MeSH Terms]) AND (
    "American Heart Association"[Affiliation] OR 
    "American College of Cardiology"[Affiliation] OR
    "American Diabetes Association"[Affiliation] OR
    "World Health Organization"[Affiliation] OR
    "Centers for Disease Control"[Affiliation] OR
    "American College of Sports Medicine"[Affiliation] OR
    "American Medical Association"[Affiliation] OR
    "National Institutes of Health"[Affiliation] OR
    "Kidney Disease Improving Global Outcomes"[Affiliation] OR
    KDIGO[Affiliation] OR
    "Infectious Diseases Society of America"[Affiliation] OR
    IDSA[Affiliation] OR
    "European Society of Cardiology"[Affiliation] OR
    ESC[Affiliation] OR
    JAMA[Journal] OR
    "New England Journal of Medicine"[Journal] OR
    Lancet[Journal] OR
    Circulation[Journal] OR
    "Diabetes Care"[Journal] OR
    "Kidney International"[Journal] OR
    "American Journal of Kidney Diseases"[Journal] OR
    "Clinical Infectious Diseases"[Journal] OR
    "European Heart Journal"[Journal] OR
    "Journal of the American College of Cardiology"[Journal]
  )" with filters:  AND 2016:2026[dp] AND humans[mh] AND hasabstract
ğŸ” Searching Cochrane reviews: What is the evidence comparing sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease? AND "Cochrane Database Syst Rev"[Journal]
ğŸ” PubMed search: "What is the evidence comparing sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease? AND "Cochrane Database Syst Rev"[Journal]"
ğŸ” Searching recent Cochrane reviews: What is the evidence comparing sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease? AND "Cochrane Database Syst Rev"[Journal] AND 2024:2026[pdat]
ğŸ” PubMed search: "What is the evidence comparing sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease? AND "Cochrane Database Syst Rev"[Journal] AND 2024:2026[pdat]"
âŒ ClinicalTrials.gov API error: 400 Bad Request
âœ… Found 5 StatPearls articles
âœ… Found 0 PubMed articles
âœ… Found 0 PubMed articles
No Cochrane reviews found
âœ… Found 59932 PubMed articles
âœ… Found 749167 PubMed articles
âœ… Found 20686 PubMed articles
âœ… Found 16172 PubMed articles
ğŸ“‹ Found 27 guideline articles from PubMed
â„¹ï¸  No drug terms detected in query, skipping PubChem search
ğŸ” Filtering evidence for relevance to query...
ğŸ—‘ï¸  Relevance filtering removed:
   PubMed articles: 11/15
   PubMed reviews: 0/8
   Cochrane reviews: 0/0
   PMC articles: 0/0
ğŸ“‹ Removed PubMed articles (off-topic):
   Removed: "ACOG Practice Bulletin No. 201: Pregestational Diabetes Mell..." (score: 20/100, reason: Disease match: diabetes)
   Removed: "Beyond the pancreas: contrasting cardiometabolic actions of ..." (score: 0/100, reason: No concept matches)
   Removed: "SGLT2 inhibitors and mechanisms of cardiovascular benefit: a..." (score: 10/100, reason: Intervention match: sglt2)
ğŸ” Applying age-based filtering...
ğŸ”„ Applying semantic reranking to improve relevance...
[SemanticReranker] Reranking 8 articles for query: "What is the evidence comparing SGLT2 inhibitors versus GLP-1 agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease?"
[SemanticReranker] Reranked 8 articles in 136ms (avg similarity: 0.531)
âœ… Reranked 8 PubMed reviews
ğŸ“š High evidence volume (57 items) - skipping Tavily regardless of score
ğŸ“Š Evidence sufficiency: 93/100 (excellent)
âœ… Skipping fallbacks - internal evidence sufficient (score: 93/100, anchors: 4)
ğŸ“Š Primary sources used: PubMed (4), Europe PMC (7), Cochrane (0), PMC (0)
â„¹ï¸  No excluded MeSH terms - skipping evidence filtering
ğŸ”“ OPEN ACCESS PRIORITY SOURCES:
   PMC Articles: 0 (FREE FULL TEXT)
   Government Guidelines: 9 (FREE)
   NCBI Books: 5 (FREE TEXTBOOKS)
   DailyMed: 0 (FREE DRUG INFO)
âœ… Evidence gathered: {
  trials: 0,
  labels: 0,
  events: 0,
  dailyMedDrugs: 0,
  aapGuidelines: 0,
  aapPolicyStatements: 0,
  rxnormDrugs: 0,
  rxnormClasses: 0,
  rxnormInteractions: 0,
  openAlexPapers: 8,
  openAlexReviews: 5,
  pubmedArticles: 15,
  pubmedReviews: 8,
  pubmedGuidelines: 27,
  pmcArticles: 0,
  pmcRecentArticles: 0,
  pmcReviews: 0,
  cochraneReviews: 0,
  cochraneRecent: 0,
  europePMCRecent: 10,
  europePMCCited: 10,
  europePMCPreprints: 3,
  europePMCOpenAccess: 10,
  semanticScholarPapers: 0,
  semanticScholarHighlyCited: 0,
  medlinePlusTopics: 0,
  medlinePlusDrugs: 0,
  guidelines: 5,
  whoGuidelines: 3,
  cdcGuidelines: 3,
  niceGuidelines: 3,
  bmjBestPractice: 3,
  cardiovascularGuidelines: 5,
  ncbiBooks: 5,
  omimEntries: 0,
  pubChemCompounds: 0,
  landmarkTrials: 5,
  pubChemBioAssays: 0,
  openIResearch: 0,
  openIReviews: 0,
  openISystematicReviews: 0,
  openICaseReports: 0,
  tavilyCitations: 0
}
ğŸ·ï¸  Using tag-based evidence ranking
âŒ Tag-filtered off-topic: "Renoprotective effects of sodium-glucose cotranspo..." (relevance: 0)
âŒ Tag-filtered off-topic: "Mechanisms of Cardiorenal Effects of Sodium-Glucos..." (relevance: 0)
ğŸ·ï¸  Tag-based filter: 44 â†’ 42 items
ğŸ“Š Final reference list: 10 items (40% high-relevance)
   - Anchors: 4
   - Primary studies: 0
ğŸ”’ Complex Scenario Detected: Capping references to reduce noise.
âš“ Injected 4 Anchor Guidelines into prompt
ğŸ† Injected 5 Landmark Trials into prompt
ğŸ“Š Evidence Sufficiency: EXCELLENT (72/100)
âœ… No Google search URLs detected in formatted evidence
âœ… doctor Mode: Found 51 evidence items from comprehensive RAG engine
âš ï¸ Excluding invalid evidence: 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - No PMID, DOI, or URL found
âš ï¸ Excluding invalid evidence: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) - No PMID, DOI, or URL found
âš ï¸ Excluding invalid evidence: From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus - No PMID, DOI, or URL found
âš ï¸ Excluding invalid evidence: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - No PMID, DOI, or URL found
âœ… Evidence quality check: 13/17 items have working links
ğŸš« Excluding restricted source: ADA/KDIGO Consensus Report: Diabetes Management in Chronic Kidney Disease (diabetesjournals.org)
ğŸš« Excluding restricted source: KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (diabetesjournals.org)
ğŸš« Excluding restricted source: 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice (doi.org)
âœ… Open access filter: 10/13 sources are accessible
ğŸ”“ Access check: 10/13 sources are freely accessible
ğŸ¤– Generating content with model: gemini-2.5-flash + Simplified Evidence System
ğŸ“ Content parts: 7 parts
ğŸ“š Evidence items available: Yes
ğŸ“ Total content length: 69080 characters
âœ… Content generated successfully
DEBUG RESPONSE: **Quick Answer**
Both **SGLT2 inhibitors** and **GLP-1 receptor agonists** significantly improve **cardiovascular outcomes** in **type 2 diabetes** patients with **established cardiovascular disease**, but their primary benefits differ. SGLT2 inhibitors primarily reduce heart failure hospitalization and renal events, while GLP-1 receptor agonists primarily reduce major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [[1]](https://pubmed.ncbi.nlm.nih.gov/32970396)[[2]](https://diabetesjournals.org/care/article/45/12/3075/147468/Consensus-Report-Diabetes-Management-in-Chronic).

**Clinical Answer**
For patients with type 2 diabetes and established cardiovascular disease, both SGLT2 inhibitors and GLP-1 receptor agonists are recommended as foundational therapies due to their distinct and complementary cardioprotective effects. SGLT2 inhibitors, such as empagliflozin 10 mg once daily or dapagliflozin 10 mg once daily, are particularly effective in reducing heart failure hospitalization and progression of chronic kidney disease, regardless of glycemic control [[3]](https://kdigo.org/guidelines/diabetes-ckd/)[[4]](https://pubmed.ncbi.nlm.nih.gov/32970396). GLP-1 receptor agonists (e.g., semaglutide 1 mg weekly, dulaglutide 1.5 mg weekly, liraglutide 1.8 mg daily) are preferred for reducing MACE [[2]](https://diabetesjournals.org/care/article/45/12/3075/147468/Consensus-Report-Diabetes-Management-in-Chronic)[[5]](https://pubmed.ncbi.nlm.nih.gov/37150579). Guidelines recommend considering both classes for additive benefits in high-risk individuals [[2]](https://diabetesjournals.org/care/article/45/12/3075/147468/Consensus-Report-Diabetes-Management-in-Chronic).

**Evidence Summary**
Current guidelines, including the KDIGO-ADA Consensus Report and the 2026 ADA Standards of Medical Care in Diabetes, strongly recommend SGLT2 inhibitors and GLP-1 receptor agonists for patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk [[2]](https://diabetesjournals.org/care/article/45/12/3075/147468/Consensus-Report-Diabetes-Management-in-Chronic)[[6]](https://diabetesjournals.org/care/issue/47/Supplement_1). Landmark trials have demonstrated distinct benefits: SGLT2 inhibitors significantly reduce heart failure hospitalizations and cardiovascular death, as shown by DAPA-HF (dapagliflozin, HR 0.74, p<0.001 for CV death or worsening HF) [[7]](https://pubmed.ncbi.nlm.nih.gov/31535829), and improve renal outcomes (e.g., DAPA-CKD, EMPA-KIDNEY, CREDENCE trials) [[1]](https://pubmed.ncbi.nlm.nih.gov/32970396)[[8]](https://pubmed.ncbi.nlm.nih.gov/36331190)[[9]](https://pubmed.ncbi.nlm.nih.gov/30990260). GLP-1 receptor agonists have consistently shown reductions in MACE (cardiovascular death, non-fatal MI, non-fatal stroke) across various trials, leading to recommendations for their use in patients with T2DM and ASCVD or high ASCVD risk [[2]](https://diabetesjournals.org/care/article/45/12/3075/147468/Consensus-Report-Diabetes-Management-in-Chronic)[[6]](https://diabetesjournals.org/care/issue/47/Supplement_1). Given their complementary mechanisms and benefits, combination therapy with both SGLT2 inhibitors and GLP-1 receptor agonists is increasingly recommended for high-risk patients to achieve broader cardiorenal protection [[2]](https://diabetesjournals.org/care/article/45/12/3075/147468/Consensus-Report-Diabetes-Management-in-Chronic).

**Clinical Recommendations**
*   **Initial Therapy**: For type 2 diabetes patients with established cardiovascular disease, initiate an SGLT2 inhibitor (empagliflozin 10 mg or dapagliflozin 10 mg daily) as a foundational therapy due to strong evidence for reducing heart failure and kidney disease progression [[3]](https://kdigo.org/guidelines/diabetes-ckd/)[[4]](https://pubmed.ncbi.nlm.nih.gov/32970396).
*   **Add-on Therapy**: If glycemic goals are not met or if further cardiovascular protection (especially MACE reduction) is desired, add a GLP-1 receptor agonist (e.g., semaglutide 1 mg weekly or dulaglutide 1.5 mg weekly) to SGLT2 inhibitor therapy [[2]](https://diabetesjournals.org/care/article/45/12/3075/147468/Consensus-Report-Diabetes-Management-in-Chronic)[[6]](https://diabetesjournals.org/care/issue/47/Supplement_1).
*   **Monitoring**: Monitor for expected side effects such as volume depletion and genital mycotic infections with SGLT2 inhibitors, and gastrointestinal intolerance with GLP-1 receptor agonists [[3]](https://kdigo.org/guidelines/diabetes-ckd/).

**Summary**
Both SGLT2 inhibitors and GLP-1 receptor agonists offer significant and distinct cardiovascular benefits for type 2 diabetes patients with established cardiovascular disease. SGLT2 inhibitors primarily reduce heart failure and kidney disease progression, while GLP-1 receptor agonists target MACE, with guidelines supporting their combined use for additive protection in high-risk individuals [[2]](https://diabetesjournals.org/care/article/45/12/3075/147468/Consensus-Report-Diabetes-Management-in-Chronic)[[3]](https://kdigo.org/guidelines/diabetes-ckd/).

## References

1. [Dapagliflozin in Patients with Chronic Kidney Disease](https://pubmed.ncbi.nlm.nih.gov/32970396)
   Heerspink HJL, Stefansson BG, Correa-Rotter R, et al. N Engl J Med. 2020. PMID:32970396. doi:10.1056/NEJMoa2025816.
   [PubMed] - [Pivotal RCT] - [High-Impact]
2. [ADA/KDIGO Consensus Report: Diabetes Management in Chronic Kidney Disease](https://diabetesjournals.org/care/article/45/12/3075/147468/Consensus-Report-Diabetes-Management-in-Chronic)
   American Diabetes Association / Kidney Disease: Improving Global Outcomes. American Diabetes Association / Kidney Disease: Improving Global Outcomes. 2022.
   [Practice Guideline] - [Anchor Guideline]
3. [KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease](https://kdigo.org/guidelines/diabetes-ckd/)
   Kidney Disease: Improving Global Outcomes. Kidney Disease: Improving Global Outcomes. 2022. doi:10.1016/j.kint.2022.06.008.
   [Practice Guideline] - [Anchor Guideline]
4. [KDIGO-ADA Consensus Report: Diabetes Management in Chronic Kidney Disease](https://pubmed.ncbi.nlm.nih.gov/36243226)
   Kidney Disease: Improving Global Outcomes / American Diabetes Association. Kidney Disease: Improving Global Outcomes / American Diabetes Association. 2022. PMID:36243226. doi:10.2337/dci22-0027.
   [PubMed] - [Anchor Guideline]
5. [American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update.](https://pubmed.ncbi.nlm.nih.gov/37150579)
   Samson SL, Vellanki P, Blonde L, et al. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2023. PMID:37150579. doi:10.1016/j.eprac.2023.02.001.
   [PubMed] - [Recent (â‰¤3y)] - [Practice Guideline]
6. [2026 ADA Standards of Medical Care in Diabetes](https://diabetesjournals.org/care/issue/47/Supplement_1)
   American Diabetes Association. American Diabetes Association. 2026. doi:10.2337/dc24-S009.
   [Practice Guideline] - [Anchor Guideline] - [Recent (â‰¤3y)]
7. [Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction](https://pubmed.ncbi.nlm.nih.gov/31535829)
   McMurray JJV, Solomon SD, Inzucchi SC, et al. N Engl J Med. 2019. PMID:31535829. doi:10.1056/NEJMoa1911303.
   [PubMed] - [Pivotal RCT] - [High-Impact]
8. [Empagliflozin in Patients with Chronic Kidney Disease](https://pubmed.ncbi.nlm.nih.gov/36331190)
   The EMPA-KIDNEY Collaborative Group. N Engl J Med. 2023. PMID:36331190. doi:10.1056/NEJMoa2204233.
   [PubMed] - [Pivotal RCT] - [High-Impact] - [Recent (â‰¤3y)]
9. [Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation](https://pubmed.ncbi.nlm.nih.gov/30990260)
   Perkovic V, Jardine MJ, Neal B, et al. N Engl J Med. 2019. PMID:30990260. doi:10.1056/NEJMoa1811744.
   [PubMed] - [Pivotal RCT] - [High-Impact]

## Follow-Up Questions

1. What are the specific contraindications and common side effects of SGLT2 inhibitors and GLP-1 receptor agonists?
2. How do these agents compare in terms of glycemic control and weight management in type 2 diabetes?
3. What is the evidence supporting the use of SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes but without established cardiovascular disease or chronic kidney disease?
ğŸ“Š CITATION VALIDATION RESULTS:
Citation Validation: PASS
Valid: 9, Invalid: 0
âœ… All citations validated successfully
âœ… All citation URLs validated successfully
ğŸ–¼ï¸  Fetching relevant medical images for doctor mode...
ğŸ“‹ Extracted image tags: { disease_tags: [ 'DIABETES', 'VTE' ], decision_tags: [] }
ğŸ–¼ï¸ Retrieving medical images for doctor mode...
ğŸ“ Expanded query: What is the evidence comparing SGLT2 (sodium-glucose cotransporter-2) inhibitors versus GLP-1 (glucagon-like peptide-1) agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease?
ğŸ“š [DOCTOR] Decomposed into 2 teaching panels
ğŸ” [DOCTOR] Panel "Type 2 Diabetes and Metabolic Risk": type 2 diabetes insulin resistance pathophysiology
ğŸ” Open-i API: https://openi.nlm.nih.gov/api/search?query=type+2+diabetes+insulin+resistance+pathophysiology&m=1&n=2&it=xg&coll=pmc&favor=r&fields=t
âœ… Found 1 Open-i images for "type 2 diabetes insulin resistance pathophysiology"
ğŸ” [DOCTOR] Panel "Pharmacologic Mechanisms": SGLT2 inhibitor mechanism
ğŸ” Open-i API: https://openi.nlm.nih.gov/api/search?query=SGLT2+inhibitor+mechanism&m=1&n=2&it=xg&coll=pmc&favor=r&fields=t
ğŸ“­ No Open-i results for: "SGLT2 inhibitor mechanism"
ğŸ“‹ Image queries: What is the evidence comparing SGLT2 (sodium-glucose cotransporter-2) inhibitors versus GLP-1 (glucagon-like peptide-1) agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease? medical diagram, pulmonary circulation anatomy diagram, pancreas anatomy islets of langerhans
ğŸ¯ Intelligent image retrieval for: "What is the evidence comparing SGLT2 inhibitors versus GLP-1 agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease?" (doctor mode)
   Intent: openi (confidence: 0.9)
   Sources: openi
   Keywords: {
  diseases: [ 'diabetes' ],
  organs: [],
  modalities: [],
  bodyParts: [],
  cancer: false,
  msk: false,
  imaging: false
}
   ğŸ”¬ Searching Open-i with multiple strategies...
   ğŸ“Š Strategy 1 - Graphics: "What is the evidence comparing SGLT2 inhibitors versus GLP-1 agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease? diagram pathophysiology"
ğŸ” Open-i API: https://openi.nlm.nih.gov/api/search?query=What+is+the+evidence+comparing+SGLT2+inhibitors+versus+GLP-1+agonists+for+cardiovascular+outcomes+in+type+2+diabetes+patients+with+established+cardiovascular+disease%3F+diagram+pathophysiology&m=1&n=6&it=xg&coll=pmc&favor=r&fields=t
ğŸ“­ No Open-i results for: "What is the evidence comparing SGLT2 inhibitors versus GLP-1 agonists for cardiovascular outcomes in type 2 diabetes patients with established cardiovascular disease? diagram pathophysiology"
   ğŸ”¬ Strategy 3 - Pathology: "diabetes pathophysiology diagram"
ğŸ” Open-i API: https://openi.nlm.nih.gov/api/search?query=diabetes+pathophysiology+diagram&m=1&n=4&it=xg&coll=pmc&at=rw&favor=r&fields=t
ğŸ“­ No Open-i results for: "diabetes pathophysiology diagram"
   ğŸ’Š Strategy 4 - Treatment: "diabetes treatment algorithm"
ğŸ” Open-i API: https://openi.nlm.nih.gov/api/search?query=diabetes+treatment+algorithm&m=1&n=3&it=xg&coll=pmc&favor=t&fields=t
âœ… Found 1 Open-i images for "diabetes treatment algorithm"
   ğŸ“Š Open-i total: 1 images (0 graphics, 0 anatomy, 0 pathology, 1 treatment)
âœ… Found 1 unique images from Open-i
ğŸ“Š Final selection: Personalized therapy algorithms for type 2 diabete...
   ğŸ¯ Intelligent retrieval: 1 images from orchestrator
   âœ… Deduplicated: 2 â†’ 2 unique images
âœ… Found 2 relevant medical images (1 open sources, 1 web results)
ğŸ“¸ Extracting images from PMC articles in evidence...
âœ… Extracted 0 images from PMC articles
âœ… doctor Mode: Found 2 images
 POST /api/chat 200 in 29.1s (compile: 40ms, render: 29.1s)
